---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040249"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T15:59:22.511611+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%

## Summary
- 10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.
- Revenue share for AVITA increases to 60% after manufacturing costs (was 50/50).
- Stedical eligible for milestone payments tied to AVITA's achievement of sales targets.
- Exclusive distribution agreement term extended to ten years from March 17, 2025.
- PermeaDerm is FDA-cleared biosynthetic wound matrix; eligible for U.S. reimbursement.

## SEC filing metadata
- accession: 0000950170-25-040249
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017025040249/0000950170-25-040249-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017025040249/rcel-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040249
- JSON: https://secwatch.observer/filing/0000950170-25-040249.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040249.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.